<SEC-DOCUMENT>0001493152-18-018103.txt : 20181231
<SEC-HEADER>0001493152-18-018103.hdr.sgml : 20181231
<ACCEPTANCE-DATETIME>20181231070035
ACCESSION NUMBER:		0001493152-18-018103
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181227
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181231
DATE AS OF CHANGE:		20181231

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARROW HEALTH, INC.
		CENTRAL INDEX KEY:			0001360214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450567010
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35814
		FILM NUMBER:		181258614

	BUSINESS ADDRESS:	
		STREET 1:		12264 EL CAMINO REAL
		STREET 2:		SUITE 350
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-704-4042

	MAIL ADDRESS:	
		STREET 1:		12264 EL CAMINO REAL
		STREET 2:		SUITE 350
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Imprimis Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20120301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSDEL PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20070912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bywater Resources, Inc
		DATE OF NAME CHANGE:	20060421
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): December 27, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>HARROW
HEALTH, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-35814</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>45-0567010</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other jurisdiction</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
        incorporation)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
        Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12264
    El Camino Real, Suite 350</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>San
    Diego, CA </B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92130</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: <B>(858) 704-4040</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Imprimis
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
    name or former address if changed since last report.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5.03 Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Name
Change</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2018, Harrow Health, Inc. (formerly, Imprimis Pharmaceuticals, Inc.) (the &ldquo;Company&rdquo;) amended its restated
certificate of incorporation (&ldquo;Amendment&rdquo;) to change its corporate name from &ldquo;Imprimis Pharmaceuticals, Inc.&rdquo;
to &ldquo;Harrow Health, Inc.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name change was previously approved by the Board of Directors. The shareholders, under Delaware General Corporation Law, were
not required to approve the name change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stockholders do not need to take any action as a result of the name change, including that there is no need to exchange their
certificates representing their shares of common stock. The current stock certificate will continue to represent their ownership
interest in the Company. Stockholders, however, may return their certificates to the transfer agent for the Company and obtain
an updated certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
press release relating to the name change being completed and reflected on The NASDAQ Capital Market is being furnished as Exhibit
99.1 to this Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01 Other Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Symbol
Change</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading symbol reflecting the new name for the company, for the common stock of the Company, on The NASDAQ Capital Market is HROW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
    </B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex3-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Restated Certificate of Incorporation for the name change, filed as of December 27, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Harrow Health, Inc. on December 31, 2018</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Imprimis
    Pharmaceuticals, Inc. </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    December 31, 2018</FONT></TD>
    <TD STYLE="width: 6%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew R. Boll</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF AMENDMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED CERTIFICATE OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPRIMIS
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &ldquo;DCGL&rdquo;)
does hereby certify:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST</B>:
That at a meeting of the Board of Directors of Imprimis Pharmaceuticals, Inc. resolutions were duly adopted in accordance with
the provisions of Section 242(b)(1) of the DGCL setting forth a proposed amendment of the Amended and Restated Certificate of
Incorporation of said corporation, declaring said amendment to be advisable and pursuant to the aforementioned section of the
DGCL that no meeting or vote of the stockholders shall be required to adopt an amendment to the Amended and Restated Certificate
of Incorporation that effects only a change to the name of a corporation. The resolution setting forth the proposed amendment
is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESOLVED</B>,
that the Amended and Restated Certificate of Incorporation of this corporation be amended by changing the Article thereof numbered
&ldquo;FIRST&rdquo; so that, as amended, said Article shall be and read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST:
The name of this Corporation is Harrow Health, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND</B>:
That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State
of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, said corporation has caused this certificate to be signed this 27th day of December, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew Boll</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
of Delaware</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary
of State</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivered
02:07 PM 12/27/2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FILED
02:07 PM 12/27/2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SR
20188383099 - File Number 4092296</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 261pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_1.jpg" ALT="" STYLE="height: 128; width: 400"></FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    99.1</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Imprimis
Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Harrow
Health, Inc. Name Reflects the Company&rsquo;s Commitment to the Future of Healthcare</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Diego, Calif. &ndash; December 31, 2018 &ndash; Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals, Inc.) (NASDAQ:
IMMY) announced it has formally changed its name and that it will trade as &ldquo;HROW&rdquo; on The NASDAQ Capital Markets beginning
at market open January 2, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
L. Baum, CEO of Harrow Health, stated, &ldquo;Our new name reflects our business model of creating, investing in, operating and
growing a diversified portfolio of healthcare businesses that meet the needs of healthcare providers and patients across America.
The future of healthcare involves rethinking our current paradigm, creating patient-centric solutions, and motivating the best
partners to act to turn vision into reality. I&rsquo;ve never been more enthusiastic about our ability to execute our strategy
and the value Harrow Health will deliver over many years to come.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health&rsquo;s businesses and subsidiaries each have strong brand equity and will continue to operate under the Harrow Health
corporate umbrella using their existing names. This includes Harrow Health&rsquo;s wholly-owned subsidiaries ImprimisRx, the nation&rsquo;s
leading ophthalmology pharmaceutical compounding business, and Park Compounding. Harrow Health&rsquo;s equity interests and royalty-rights
in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, and Radley Pharmaceuticals remain
in Harrow Health as well.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Harrow Health</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nation&rsquo;s leading ophthalmology
pharmaceutical compounding business, <U>ImprimisRx</U>. The company holds large equity positions in <U>Eton Pharmaceuticals</U>,
<U>Surface Pharmaceuticals</U>, <U>Melt Pharmaceuticals</U>, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded
as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by
Eton, Surface, Melt, Mayfield and Radley. Harrow intends  to create, invest in and grow paradigm shifting health care
businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the
corporate website by <U>clicking here</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be considered such &ldquo;forward-looking statements.&rdquo;
Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties which
may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ from those predicted include our ability to make commercially available our compounded
formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related
to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies,
physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual
property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds
when necessary; risks related to research and development activities; the projected size of the potential market for our technologies
and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies,
outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties
are more fully described in Harrow Health&rsquo;s filings with the Securities and Exchange Commission, including its Annual Report
on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC&rsquo;s web site at
<U>www.sec.gov</U>. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are
made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon
Patton</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jpatton@harrowinc.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">858.704.4587</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
Harrow Health, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_1.jpg
<TEXT>
begin 644 ex99-1_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #< K$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BFNZ11M)(RHBC+,QP /4FN&UWXO^#]#W(NH'4;A?^65@OF_^/Y"
M?^/9]J:3>PFTMSNZCGN(;6!Y[B6.&%!EY)&"JH]23TKYZU[X]Z[>[XM%L;?3
M8SP)9/WTOU&0%'T(;ZUYMJ^NZMK\_G:MJ-S>N#E?.D+*O^ZO1?P K146]S&5
M>*V/I'7OC-X0T;='!=R:I<#C98KN7/;]X<*1]"?I7%0_M#3_ -HDS^'8Q8G
M"QW),J^IR5PWTP/K7B=%:JE%&+KR>Q]6:#\6/!^O;434Q8W#?\L;\>2?INSL
M)]@QKM58,H92"",@CO7P]6SH?BWQ!X:8?V/JUS:H,GR@VZ(Y_P!ALKGWQ4.C
MV-(XC^9'V317@N@_M WD6V+Q!I$=PG ,]DVQP/\ <8X)_P"!*/:O3M ^)/A/
MQ&4CL]6BCN7P!;77[F3)[ -PQ_W2:S<)+<VC4C+9G64445!84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116'X
MI\6Z3X.TQ;_5I9%C=_+C6*,NTCX)P,<#@'DD#WH2N#=C<I"0H))  Y)->"Z]
M^T!>2EXM TB.W3D">];>Y'^XIP#_ ,"85YEKGB[Q#XD)_M?5[JZ0X_<EML7'
M^PN%S[XS6JI2>YC*O%;:GTIKWQ6\'Z!N235%O+A?^6%B/.;/IN'R@^Q85YCK
MOQ^U6YW1:'ID%DAR!-<GS9/J%&%4_7=7C]%:JE%&$J\GL:NM>)M<\1R;]8U6
MZO!NW!)'_=J?4(,*OX 5E445I:QDVWN%%%% @HHHH **** "@@$8-%% '1Z#
MX\\3^&MJ:9K%PD"X MY3YL6/0*V0O_ <&O3]!_:"!VQ^(='(/>XL&R/^_;GC
MZ[C]*\-HJ7"+W-(U91V9]@Z#XZ\,^)MJZ7J]O+,W2W<^7+[_ "-@GZ@8KH:^
M'" >HS77:#\3/%OATJMKJTEQ;J?^/>\_?(1Z<_,H]E(K)T>QM'$+JCZUHKQG
M0?V@+&;9%K^E2VK\ SVA\Q"?4J<,H^FZO5]'UG3_ !!I<.I:7<K<6<V=D@4K
MG!P>" 0<@]163BX[F\9QEL7Z***DH**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:HI.$7T*56:ZGV=H'B'2O$VF+J&D7:7-N3M..&1O[K*>5/L?8]#6I7QYX/\
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M'_D<1_U[2?S6O::X,3\9ZF#_ (?S"N>\>?\ )/O$?_8,N/\ T6U=#7/>//\
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MK_KQ/_HQJJE\1%?X#R.OJ+X+?\DNT[_KK/\ ^C6KY=KZB^"W_)+M._ZZS_\
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M+X0\01^*/"FG:P@ :XB'FH.B2#Y77Z!@<>V*PK1UN=-"5URGG7[0?_(M:/\
M]?I_]%M7S[7T%^T'_P BUH__ %^G_P!%M7S[6E+X3*O\8C'",1V%?3$/P0\&
M201N8;[+*"?]*/I7S,_^K;Z&OM^U_P"/2'_KFO\ *IJMJUBZ$4[W/E'XC>"I
M/!/B5K5-[Z=<@RV<K=U[H3_>4D#Z%3WKD*^O?'?A&#QGX8GTU]B72_O;29O^
M6<HZ9QV/(/L3WQ7R/=6L]C=S6EU$T-Q [1RQMU5@<$?G54Y\R(K4^5W6Q>\/
M:]?>&-=M=7T]\3V[9*D_+(I^\C>Q''MU'(%?7N@:Y9>)-#M-7T]RUO<IN ;[
MR'H5;W!!!^E?%]>D_"#QW_PB^N_V7?RA=)U!P&9FPL$W0/Z 'A6_X"<X4TJL
M+JZ'1J<KLSZ9KQ_]H/\ Y%K1_P#K]/\ Z+:O8*\?_:#_ .1:T?\ Z_3_ .BV
MK&G\2.FK\#/GVD8X1B.PI::_^K;Z&NLX%N?3,/P0\&201N8;[+*"?]*/I7B_
MQ&\%2>"?$K6J;WTZY!ELY6[KW0G^\I('T*GO7U=:_P#'I#_US7^5<_X[\(P>
M,_#$^FOL2Z7][:3-_P LY1TSCL>0?8GOBN:-1IZG;.DG'0^0JT_#VO7WAC7;
M75]/?$]NV2I/RR*?O(WL1Q[=1R!5&ZM9[&[FM+J)H;B!VCEC;JK X(_.HJZ=
MSBU3/M#0-<LO$FAVFKZ>Y:WN4W -]Y#T*M[@@@_2M*OF;X0>._\ A%]=_LN_
ME"Z3J#@,S-A8)N@?T /"M_P$YPIKZ9KDG'E=COISYU<\X^-/AAM>\%F^MX]]
MWI3&X4 <M$1B0#\ &_X!BOF2ON*OF3XJ?#B7PGJ,FJZ;"6T.Y?(VC_CU<G[A
M_P!DG[I_X"><%M*4_LLQKT[^\CSBO2?AG\4I?!__ !*M466XT5V++LY>V8\D
MJ.ZD\E?<D<Y!\VHK9Q35F<\9.+NC[-T?Q-H?B"!9=)U6UNP1G;'(-Z_[RGYE
M/L0*EU37M(T2$S:IJ5I9H!D&:55)^@/)/L*^+"JMU /U% 55Z*!]!67L?,W^
ML:;'K7Q-^+:^([630] \R/3'.+BY=2K7 '\*@\JG<YP3TP!G=Y-116L8J*LC
M&4W)W85])? _PP^C>$Y-7N8RMSJS+(H/:!<^7^>6;W#+7EOPP^'4WC'5%O;Z
M)ET.V?\ ?,>/M##_ )9J?3^\1T''4\?4"(L:*B*%11A548 'H*QJS^RC>A#[
M3'5YW\:=".K_  ^GN8T+3Z;(MTN!R4'RO^ 5BW_ 17HE0W5K#>V<]I<1B2">
M-HY$/1E88(_(UC%V=SHDKJQ\1T5=U?3)M%UF^TN<DRV<[PLV,;MIP&^A'/XU
M2KM/.:MH%>M_ 30?MOB:]UN5 8]/A\N(D?\ +63(R#[*&!_WQ7DE?57PDT+^
MPOAWIX==L]]F]E^KXV_3Y @^H-9U7:)K0C>5^QW%?,7QIT'^Q_'TMW&FVWU.
M,7"D#C>/E<?7(#'_ 'Z^G:\Q^.>@_P!I^"%U.-,SZ7,),@9/E/A7 _'8Q]EK
M&F[2.FK'FB?-=%%%=1P!TKZS^&&A_P!@?#W2K=T"SSQ_:IN,'=)\V#[A2J_\
M!KYH\':'_P ))XPTK22NZ*XG'G#./W2_,_/^ZK?C7V-6%9]#JP\=Y!1116!T
MA1110 4444 %>1_M!?\ (HZ5_P!A$?\ HJ2O7*\C_:"_Y%'2O^PB/_14E73^
M)$5/@9\\UU'A3_CUN?\ KH/Y5R]=1X4_X];G_KH/Y5W0^(\RI\)T%%%%;'.;
M?A778_#FLG4)('GQ"\:HK 9)QC)/0<>]:VJ?$O7K\LMJ8K"(]!$NY\>[-_0"
MN.HJ'3BWS-&BJSC'E3T)+BXGNYC-<SRSRGK)*Y=OS-1T5H:9H.JZR1_9^GSS
MJ?\ EH%PG_?1POZU3:2U(2<GH9]'2O1=+^%%W+A]5OXX%[Q6PWL1_O'@'\#7
M::7X(\/Z3M:*P2:8?\M;G]XV?49X!^@%8RQ$%MJ=$,)4EOH>,Z7X=UC6=IL-
M.GEC/24C;'_WTV ?PKM-+^$\[X?5M16,=XK4;C_WTPP/R->IT5SRQ,WMH=4,
M'"/Q:F#I7@W0=(*O;Z?&\PY\Z?\ >/GU!/3\,5O445@Y-ZLZHQ459(****0P
MKYY_:!_Y&S2O^O$_^C&KZ&KYY_:!_P"1LTK_ *\3_P"C&K2E\1C7^ \CKZB^
M"W_)+M._ZZS_ /HUJ^7:^HO@M_R2[3O^NL__ *-:M:WPF6'^)GH%?%GB"1/^
M$FU;YU_X_9^__31J^TZ*QA/E-ZE/G1\-^9'_ 'U_.O:_V=F5K_Q#M8']U;]#
M[R5[S152J\RM8F%%1=[A11161L>5?']@O@*R)( _M./K_P!<Y:^</,C_ +Z_
MG7W)16L*G*K6,9T5-WN?#1DCP?G7\Z^R?#ES#:>!=)NKB5(X(M,ADDD8X55$
M0))/H!6Y12G4YATZ?)U/C'Q/XA/B;Q/J.LRL%^U3%D5B,I&.$4^X4**R?,C_
M +Z_G7W)15JM;H0Z%W>Y\S?!#P^NM>-CJ4@#VVE1^<>A!E;*H#_X\WU45],T
M45E.7,[FL(*"L@HHHJ2S$\7^'X_%'A34='? :XB/E,>BR#YD/T# 9]J^.)/W
M,KQ3?NY48JZ-P58<$'W!K[BHK2%3E,JE)3/AOS(_[Z_G7M7P \4)'>7_ (9F
ME7;,/M=J,C[P $BCZC:<?[+&O>J*<JO,K6%"CRNZ9X]^T*RKX9T?) _TT]3_
M -,VKY\\R/\ OK^=?<E%$*G*K6"=%3=[GPR\B>6WSKT/>ON&U_X](?\ KFO\
MJEHJ9SYBJ=/D"O$OCEX'\R+_ (2[3XCO0*FH*O=1PLOX<*?;:> IKVVBE&3B
M[HJ45)69\-^9'_?7\Z0R1D8+K^=?<M%:^V\C#ZNNYY9\&?'R^(M'_L*_N ^J
M6$8V,QR9X!@!O=EX!]?E/))JC^T*RKX9T?) _P!-/4_],VKV&BL^:TN9&SC>
M/*V?#?F1_P!]?SIKR)Y;?.O0]Z^YJ*T]MY&7U==R*U_X](?^N:_RJ6BBL#H/
M$OCEX'\R+_A+M/B.] J:@J]U'"R_API]MIX"FO"/,C_OK^=?<E%:QJM*QC.B
MI.Y\-&2,C!=?SKZ2^#/CY?$6C_V%?W ?5+",;&8Y,\ P WNR\ ^ORGDDUZG1
M1.IS*UAPI<CNF%1W%O!=VTEM<PQS02J4DBD4,KJ>""#P14E%9&IX3XR^!,RR
M27OA*57C/)T^=\,OM&YX/T8C_>/2O']3TK4=%NOLVJ6-Q9S<X2>,IN]QGJ/<
M<5]K5%<6T%W"T-S#'-$WWDD4,I^H-:QJM;F,J$7MH?$5%?7D_P ._!URVY_#
M6F*?^F=NL?\ Z#BB#X=>#;=MR>&M,8_]-+=9!^39J_;+L9_5WW/DW3M,O]8N
MA;:997%Y/_<MXRY'N<=![FO7_!OP)N)9([SQ9((8@0?[/@DR[^SN. /923SU
M%>YVUK;V4"P6L$4$*](XD"J/P%35$JK>QI&A%:O4AM+2WL+2*UM((X+>)0L<
M42A54#L .E3445D;!1110!\W?';1!IOC2'5$4+%J< 9CGK+'A6_\=\O]:\MW
M+_>'YU]N7%G:W@47-M#.%Y42H&Q],U!_8NE?] RR_P"_"_X5M&K96L<\Z',[
MW/D+PKHI\2^*],T=>5NIPLFT\B,?,Y'N%#&OLI55$"JH55&  , "JT&F6%M*
M)8+&VBD' >.)5(_$"K51.?,:4Z?(@JMJ%C!J>FW5A=*6M[J%X95!ZJP(/Z&K
M-%0:'Q-J5C+I&JW>FW1 GM)G@D]V4D$CV.,U5W+_ 'A^=?;$NE:=/*TLUA:R
M2,<L[PJ2?J2*9_8NE?\ 0,LO^_"_X5O[;R.9X?S/$OV?M#\[4=4U^1<I @M(
M6QD%FPS_ (@!/P<U[W45O:V]I&8[:"*%"=Q6- H)]<"I:RE+F=S>$>56"BBB
MI*"BBB@ HHHH *\C_:"_Y%'2O^PB/_14E>N5Y'^T%_R*.E?]A$?^BI*NG\2(
MJ? SYYKJ/"G_ !ZW/_70?RKEZZCPI_QZW/\ UT'\J[H?$>94^$Z"BBBMCG+6
MGZ;>:M>+:6%NT\[ D(I X'<DD "NWTOX4W\^U]4O8K9>ICA'F/\ 0DX /YUG
M_#'_ )'$?]>TG\UKVFN6O6E&7*CNPU"$X\TCF]+\!^'M*VLEB+F5?^6MT?,.
M?7!^4'Z 5T@    P!T HHKC<G+=G=&,8JT58**S]5UW2M"MQ/JNHVME&?NF>
M4+N]@#R3["O-M=^/>@V6Z/1K*YU.0=)&_<1?FPW?^._C346]@E.,=V>LU2U'
M5].TF+S-0O8+=3T$C@%OH.I_"OF77OC#XPUI72._738""/+L5V'_ +[.6S]"
M*ORNTDSR2,SR,<L[')/U)K>GA^;=G-5Q2C\*/6-4^*NFV^4TRTFO&_YZ2?ND
M^O(+'\A7%ZIX^\1:GE?MGV2(_P %H-G_ (]RWZUS-%=,:,([(XIXBI/=GO/@
M5F?P7IK.Q9BC$ECDD[VKH:YWP'_R).E_]<V_]#:NBK@J?&SU:7P+T"OGG]H'
M_D;-*_Z\3_Z,:OH:OGG]H'_D;-*_Z\3_ .C&ITOB(K_ >1U]1?!;_DEVG?\
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M^)_^?^/_ ,!T_P */^%B^)_^?^/_ ,!T_P *Y:BCV<.P>VJ?S,ZG_A8OB?\
MY_X__ =/\*/^%B^)_P#G_C_\!T_PKEJ*/9P[![:I_,SJ?^%B^)_^?^/_ ,!T
M_P */^%B^)_^?^/_ ,!T_P *Y:BCV<.P>VJ?S,ZG_A8OB?\ Y_X__ =/\*/^
M%B^)_P#G_C_\!T_PKEJ*/9P[![:I_,SJ?^%B^)_^?^/_ ,!T_P */^%B^)_^
M?^/_ ,!T_P *Y:BCV<.P>VJ?S,ZG_A8OB?\ Y_X__ =/\*/^%B^)_P#G_C_\
M!T_PKEJ*/9P[![:I_,SJ?^%B^)_^?^/_ ,!T_P */^%B^)_^?^/_ ,!T_P *
MY:BCV<.P>VJ?S,ZG_A8OB?\ Y_X__ =/\*/^%B^)_P#G_C_\!T_PKEJ*/9P[
M![:I_,SJ?^%B^)_^?^/_ ,!T_P */^%B^)_^?^/_ ,!T_P *Y:BCV<.P>VJ?
MS,ZG_A8OB?\ Y_X__ =/\*/^%B^)_P#G_C_\!T_PKEJ*/9P[![:I_,SJ?^%B
M^)_^?^/_ ,!T_P */^%B^)_^?^/_ ,!T_P *Y:L'7KJXM[ZR6&:2-7/S!6QG
MD4G""5[#52HW;F9Z/_PL7Q/_ ,_\?_@.G^%'_"Q?$_\ S_Q_^ Z?X5RQZFBG
M[.'87MJG\S.I_P"%B^)_^?\ C_\  =/\*/\ A8OB?_G_ (__  '3_"N6HH]G
M#L'MJG\S.I_X6+XG_P"?^/\ \!T_PH_X6+XG_P"?^/\ \!T_PKEJ*/9P[![:
MI_,SJ?\ A8OB?_G_ (__  '3_"C_ (6+XG_Y_P"/_P !T_PKEJ*/9P[![:I_
M,SJ?^%B^)_\ G_C_ / =/\*/^%B^)_\ G_C_ / =/\*Y:BCV<.P>VJ?S,ZG_
M (6+XG_Y_P"/_P !T_PH_P"%B^)_^?\ C_\  =/\*Y:BCV<.P>VJ?S,ZG_A8
MOB?_ )_X_P#P'3_"C_A8OB?_ )_X_P#P'3_"N6HH]G#L'MJG\S.I_P"%B^)_
M^?\ C_\  =/\*/\ A8OB?_G_ (__  '3_"N6HH]G#L'MJG\S.I_X6+XG_P"?
M^/\ \!T_PH_X6+XG_P"?^/\ \!T_PKEJ*/9P[![:I_,SJ?\ A8OB?_G_ (__
M  '3_"C_ (6+XG_Y_P"/_P !T_PKEJ*/9P[![:I_,SJ?^%B^)_\ G_C_ / =
M/\*[GX=^(]4U\:E_:4ZR^1Y7EXC5<9W9Z#V%>.UZ;\(NFL_6'_V>LJT(J#:1
MMAZDY5$FSTVBBBN ]0**** "O(_V@O\ D4=*_P"PB/\ T5)7KE>1_M!?\BCI
M7_81'_HJ2KI_$B*GP,^>:ZCPI_QZW/\ UT'\JY>NH\*?\>MS_P!=!_*NZ'Q'
MF5/A.@HHHK8YSL?AC_R.(_Z]I/YK7M->+?#'_D<1_P!>TG\UKVFN#$_&>I@_
MX?S"L/QI<36G@;7KFVF>&>+3YWCDC;:R,(R001T(]:W*Y[QY_P D^\1_]@RX
M_P#1;5A'<Z7L?(5Q<3W=P]Q<S2SSN<O+*Y=V^I/)J.BBNT\X1ONGZ5Z4WWC]
M:\U;[I^E>E-]X_6M:?4QJ]!****T,3WCP'_R).E_]<V_]#:NBKG? ?\ R).E
M_P#7-O\ T-JZ*O+J?&SVZ7P+T"OGG]H'_D;-*_Z\3_Z,:OH:OGG]H'_D;-*_
MZ\3_ .C&ITOB(K_ >1U]1?!;_DEVG?\ 76?_ -&M7R[7U%\%O^27:=_UUG_]
M&M6M;X3+#_$ST"OFJZ_X_;C_ *ZO_,U]*U\U77_'[<?]=7_F:K"]3/';1(J[
MSP9X&T[Q)HLE[=W-Y%(L[1!860+@ 'NIYYK@Z]B^%?\ R*DW_7V__H*UM7DX
MPNC##0C*I:2/+M>T^+2M>O;"!Y'B@DV*TA!8C ZX 'Z5G5N>,?\ D<M6_P"N
MY_D*PZTB[Q1C-6DTCM_!/@O3_$^FW-S>7%W$\4_E@0,@!&T'G*GGFN=\3:7#
MHOB.]TVW>5X8"@5I2"QRBL<X '4GM7HOPF_Y 5__ -??_LBUQ'CW_D>=5_WH
M_P#T4E90DW5E%O0Z*D(JA&26O_#G.5L^%=(@UWQ%;:=<R2QQ2AR6B(##"D\9
M!';TK&KJ?AW_ ,CQ8_[LO_H#5K-VBVC"DDYI,[7_ (5-HG_/_J?_ '\C_P#C
M='_"IM$_Y_\ 4_\ OY'_ /&Z3XHWUY8Z=IS6=Y<VS-,P8P3-&6&WH=I&:\S_
M .$@UO\ Z#>I_P#@9)_\57-356<>;F.NK*C3ERN!Z;_PJ;1/^?\ U/\ [^1_
M_&Z\S\0:=#I'B"]T^!Y'B@<*K2$%CP#S@ =_2D_X2#6_^@WJ?_@9)_\ %51F
MFFN9FFGEDFE<Y:21RS-]2>36U.$XOWG<YZLZ<E:$;#****U,0) !)Z"O4]+^
M%=A-I=M+J-W?Q7CQAI8XF0*A/.WE2>.G6N0\#:-_;7BFW1UW6]M_I$V>A"GY
M1^+8X],UZOJOB>#2_$NE:0X4F]SO8GF//"?]]-D?A7-7G*_+ [,-2@XN<]MC
MQ/6]+DT76[O3I"28)"%8_P 2'E3^((JA7I_Q6T7=':ZW$O*?Z//CT/*'\#D?
M\"%>85M3GSQ3,*U/V<W$****LR/2/#/P[TK6_#MIJ-Q=WZ2S!BRQ.@488CC*
M$]O6O/+J)8+R>%22L<K(">N 2.:]Q\ ?\B/IG^Z__H;5XCJ'_(3O/^N\G_H1
MK"E*3G)-G57A&,(M+<KT445N<IWW@[P+IOB/0S?7=U>Q2B9H]L+H%P,>JD]_
M6N@_X5-HG_/_ *G_ -_(_P#XW7EEMJNI6<7E6FI7MO%G.R&X=%SZX!Q6]X3U
MK5KCQ9ID4^K:A+$\P#))=2,K#!X()P:YYPJ:M2T.JG.EI%PU.U_X5-HG_/\
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MQ'_7M)_-:]IK@Q/QGJ8/^'\PKGO'G_)/O$?_ &#+C_T6U=#7/>//^2?>(_\
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MTJC2]XN5:DI-.![[H7A^P\.VTMO8+((Y9/,;>Y8YP!_2O'?'O_(\ZK_O1_\
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M1_5<?]\FJH32FX]&1B:;=-2>ZW."HHHKL///=O '_(CZ9_NO_P"AM7B.H?\
M(3O/^N\G_H1KV[P!_P B/IG^Z_\ Z&U>(ZA_R$[S_KO)_P"A&N:A\<CLQ/\
M#A_70KT445TG&%;G@[_D<M)_Z[C^1K#K<\'?\CEI/_7<?R-3/X653^->IZ-\
M5/\ D5(?^OM/_06KQVO8OBI_R*D/_7VG_H+5X[66&_AG1C/XH4445N<I[%\*
M_P#D5)O^OM__ $%:OZA\/]"U/4)[VY2X,T[;W*S$#/TJA\*_^14F_P"OM_\
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M1<OO^OUO_1:5AB/X9TX3^+]YPOCW_D>=5_WH_P#T4E<Y71^/?^1YU7_>C_\
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M'_HMJX?2OBK?P;8]4LXKI!P983Y;_4CH3]-M;'B/QKH6M^ /$$4%X(;A]-G
M@N!Y;$F-L 9X8^P)KF=&<7JCMC7IS6C/EZBBBN@XQ&^Z?I7I3?>/UKS5ONGZ
M5Z4W4GL>E:T^IE5Z"4445H8GO'@/_D2=+_ZYM_Z&U=%7.^ _^1)TO_KFW_H;
M5T5>74^-GMTO@7H%?//[0/\ R-FE?]>)_P#1C5]#5\\?M D'Q;I8R,BQY'_
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MDY)-LG/Z4J-54[W0\11=6UGL?.^1ZT9'K7T/_P (YH?_ $!M._\  5/\*/\
MA'-#_P"@-IW_ ("I_A6_UJ/8YOJ4NY\\9'K1D>M?0_\ PCFA_P#0&T[_ ,!4
M_P */^$<T/\ Z VG?^ J?X4?6H]@^I2[GSQD>M&1ZU]#_P#".:'_ - ;3O\
MP%3_  H_X1S0_P#H#:=_X"I_A1]:CV#ZE+N?/&1ZT9'K7T/_ ,(YH?\ T!M.
M_P# 5/\ "C_A'-#_ .@-IW_@*G^%'UJ/8/J4NY\\9'K1D>M?0_\ PCFA_P#0
M&T[_ ,!4_P */^$<T/\ Z VG?^ J?X4?6H]@^I2[GSQD>M&1ZU]#_P#".:'_
M - ;3O\ P%3_  H_X1S0_P#H#:=_X"I_A1]:CV#ZE+N?/&1ZT9'K7T/_ ,(Y
MH?\ T!M._P# 5/\ "C_A'-#_ .@-IW_@*G^%'UJ/8/J4NY\\9'K1D>M?0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
